- Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Bioorganic & medicinal chemistry letters (2009-10-20)
Theodore C Jessop, James E Tarver, Marianne Carlsen, Amy Xu, Jason P Healy, Alexander Heim-Riether, Qinghong Fu, Jerry A Taylor, David J Augeri, Min Shen, Terry R Stouch, Ronald V Swanson, Leslie W Tari, Michael Hunter, Isaac Hoffman, Philip E Keyes, Xuan-Chuan Yu, Maricar Miranda, Qingyun Liu, Jonathan C Swaffield, S David Kimball, Amr Nouraldeen, Alan G E Wilson, Ann Marie Digeorge Foushee, Kanchan Jhaver, Rick Finch, Steve Anderson, Tamas Oravecz, Kenneth G Carson
PMID19836232
RÉSUMÉ
A series of deoxycytidine kinase inhibitors was simultaneously optimized for potency and PK properties. A co-crystal structure then allowed merging this series with a high throughput screening hit to afford a highly potent, selective and orally bioavailable inhibitor, compound 10. This compound showed dose dependent inhibition of deoxycytidine kinase in vivo.
MATÉRIAUX
Numéro du produit
Marque
Description du produit
Le tarif et la disponibilité ne sont pas disponibles actuellement.